Cargando…

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis

Myelofibrosis (MF) is a hematologic neoplasm arising as a primary disease or secondary to other blood malignancies. Both primary and secondary MF develop progressive fibrosis of bone marrow, displacing normal hematopoietic cells to other organs and disrupting normal production of mature blood cells....

Descripción completa

Detalles Bibliográficos
Autores principales:	Luker, Gary D., Nguyen, Huong (Marie), Hoff, Benjamin A., Galbán, Craig J., Hernando, Diego, Chenevert, Thomas L., Talpaz, Moshe, Ross, Brian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Grapho Publications, LLC 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872873/ https://www.ncbi.nlm.nih.gov/pubmed/27213182 http://dx.doi.org/10.18383/j.tom.2016.00115

Ejemplares similares

Primary myelofibrosis evolving to an aplastic appearing marrow
por: Schaefer, Jordan K., et al.
Publicado: (2018)

Semiautomated Workflow for Clinically Streamlined Glioma Parametric Response Mapping
por: Keith, Lauren, et al.
Publicado: (2016)

Repeatability of Quantitative Magnetic Resonance Imaging Biomarkers in the Tibia Bone Marrow of a Murine Myelofibrosis Model
por: Ross, Brian D., et al.
Publicado: (2023)

Potential for Early Fracture Risk Assessment in Patients with Metastatic Bone Disease Using Parametric Response Mapping of CT Images
por: Hoff, Benjamin A., et al.
Publicado: (2015)

Multiparametric MRI to quantify disease and treatment response in mice with myeloproliferative neoplasms
por: Robison, Tanner H., et al.
Publicado: (2022)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy
por: Ross, Brian D., et al.
Publicado: (2022)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016)

MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment
por: Galbán, Stefanie, et al.
Publicado: (2017)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
por: Talpaz, Moshe, et al.
Publicado: (2018)

Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling
por: Reynolds, Samuel B., et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

The Impact of Sources of Variability on Parametric Response Mapping of Lung CT Scans
por: Boes, Jennifer L., et al.
Publicado: (2015)

Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment
por: Galbán, Craig J., et al.
Publicado: (2015)

DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma
por: Galbán, Stefanie, et al.
Publicado: (2012)

Histographic analysis of oedema and fat in inflamed bone marrow based on quantitative MRI
por: Bray, Timothy J. P., et al.
Publicado: (2020)

Knee subchondral bone perfusion and its relationship to marrow fat and trabeculation on multi-parametric MRI and micro-CT in experimental CKD
por: Wang, Chao-Ying, et al.
Publicado: (2017)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Multi-parametric quantitative MRI reveals three different white matter subtypes
por: Foucher, Jack R., et al.
Publicado: (2018)

Morphological and Immunophenotypical Changes of Human Bone Marrow Adipocytes in Marrow Metastasis and Myelofibrosis
por: Dello Spedale Venti, Michele, et al.
Publicado: (2022)

Improved Repeatability of Mouse Tibia Volume Segmentation in Murine Myelofibrosis Model Using Deep Learning
por: Kushwaha, Aman, et al.
Publicado: (2023)

In vivo imaging of tau pathology using multi-parametric quantitative MRI
por: Wells, J.A., et al.
Publicado: (2015)

Exercise-induced muscle damage: multi-parametric MRI quantitative assessment
por: Lyu, Xiaohong, et al.
Publicado: (2021)

Comparison of hyperpolarized (3)He-MRI, CT based parametric response mapping, and mucus scores in asthmatics
por: Carey, Katherine J., et al.
Publicado: (2023)

Quantitative MRI and spectroscopy of bone marrow
por: Karampinos, Dimitrios C., et al.
Publicado: (2017)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
por: Harrison, Claire N., et al.
Publicado: (2021)

Modeling the Presence of Myelin and Edema in the Brain Based on Multi-Parametric Quantitative MRI
por: Warntjes, Marcel, et al.
Publicado: (2016)

P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
por: Harrison, Claire, et al.
Publicado: (2023)

Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
por: Latifoltojar, A, et al.
Publicado: (2015)

Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis
por: Desterke, Christophe, et al.
Publicado: (2015)

Feasibility of function‐guided lung treatment planning with parametric response mapping
por: Matrosic, Charles K., et al.
Publicado: (2021)

Imaging Sensitivity of Quiescent Cancer Cells to Metabolic Perturbations in Bone Marrow Spheroids
por: Cavnar, Stephen P., et al.
Publicado: (2016)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)

Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study
por: Slot, Stefanie, et al.
Publicado: (2023)

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
por: Talpaz, Moshe, et al.
Publicado: (2013)

Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer
por: Brisset, Jean-Christophe, et al.
Publicado: (2015)

Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients
por: Ojeda‐Uribe, Mario, et al.
Publicado: (2016)

Leptin receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis
por: Decker, Matthew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e18unol1dbf6m5q2tb87g1hnba